Human arylamine N-acetyltransferase 1 (NAT1) is a phase II cytosolic enzyme responsible for the activation or deactivation of many arylamine compounds including pharmaceuticals and environmental carcinogens. NAT1 is highly polymorphic and has been associated with altered risk toward many cancers. NAT1*14B is characterized by a single nucleotide polymorphism in the coding region (rs4986782; 560G>A; R187Q). NAT1*14B is associated with higher frequency of smoking-induced lung cancer and is the most common "slow acetylator" arylamine N-acetyltransferase 1 genetic variant. Previous studies have reported decreased N-and Oacetylation capacity, and increased proteasomal degradation of NAT1 14B when compared to the referent, NAT1 4. The current study is the first to investigate NAT1*14B expression using constructs that completely mimic NAT1 mRNA by including the 5'-and 3'-UTRs together with the open reading frame of the referent, NAT1*4, or variant, NAT1*14B. Our results show that NAT1 14B is not simply associated with "slow acetylation". NAT1 14B-catalyzed acetylation phenotype is substrate dependent, and NAT1 14B exhibits higher N-and O-acetylation catalytic efficiency as well as DNA adducts following exposure to the human carcinogen, 4-aminobiphenyl.
Introduction
Human arylamine N-acetyltransferase 1 (NAT1) is a phase II cytosolic enzyme responsible for the biotransformation of many arylamine compounds including pharmaceuticals and environmental carcinogens (Hein et al., 2000) . NAT1 catalyzes both arylamine Nacetylation and hydroxyarylamine O-acetylation. Genetic polymorphisms in NAT1 can alter the amount of NAT1 protein and result in modified enzymatic activity. In addition to bioactivation of arylamines, recent studies have provided evidence that NAT1 is involved in density dependent cell growth and survival. Studies have shown that overexpression of NAT1 increased density dependent cell proliferation, whereas knock-down of NAT1 resulted in marked change in cell morphology, an increase in cell-cell contact inhibition and a loss of cell viability at confluence (Adam et al., 2003; Tiang et al., 2011) .
Molecular epidemiological studies have reported associations between NAT1 genetic polymorphisms and altered risk for developing several types of cancer including urinary bladder (Gago-Dominguez et al., 2003) , breast (Ambrosone et al., 2007; Millikan et al., 1998; Zheng et al., 1999) , colorectal (Bell et al., 1995; Lilla et al., 2006) , lung (Wikman et al., 2001) , nonHodgkin lymphoma (Morton et al., 2006) and pancreatic (Li et al., 2006) . The only known endogenous NAT1 substrate is p-aminobenzoylglutamate, a catabolite of folate (Wakefield et al., 2007) . NAT1 has been associated with various birth defects (Jensen et al., 2005; Lammer et al., 2004 ) that may be related to deficiencies in folate metabolism. The most common NAT1 variant allele associated with reduced acetylator phenotype is NAT1*14B. The allelic frequency for NAT1*14B in the Lebanese population was determined to be 23.8% (Dhaini and Levy, 2000) , while American, German, French, and Canadian NAT1*14B allelic frequencies are less than 5% (Doll and Hein, 2002 ) NAT1*14B is likely to be very prevalent in other countries in the middle east, however allelic frequencies for many of those populations are not available.
5 NAT1*14B has been associated with an increased risk of smoking-induced lung cancer (Bouchardy et al., 1998) .
NAT1*14B is characterized by a single nucleotide polymorphism (SNP) G560A
(rs4986782) located in the open reading frame (ORF). G560A results in an amino acid substitution R187Q. Computational homology modeling based on the NAT1 crystal structure indicate that the side chain of R187 is partially exposed to the domain II beta barrel, the protein surface, and the active site pocket (Walraven et al., 2008) . Interactions with these domains serve to stabilize the protein and help shape the active site pocket. The substitution of arginine for glutamine results in at least partial loss of these stabilizing hydrogen bonds resulting in destabilization of the NAT1 structure. Therefore, homology modeling predicts that NAT1
binding of acetyl coenzyme A (AcCoA), active site acetylation, substrate specificity and catalytic activity could be affected by the R187Q substitution (Walraven et al., 2008) .
Previous studies have reported NAT1*14B to be associated with a reduced N-acetylation phenotype. For example, in peripheral blood mononuclear cells, NAT1 14B was reported to result in reduced N-acetyltransferase activities and protein levels (Hughes et al., 1998) .
Recombinant NAT1 14B expression in yeast demonstrated reduced N-and O-acetylation,
protein levels and increased proteasomal degradation (Butcher et al., 2004; Fretland et al., 2001; 2002) . NAT1 14 expressed in mammalian cells also resulted in decreased V max but increased substrate K m towards p-aminobenzoic acid (PABA) (Zhu and Hein, 2008) .
Modifications in NAT1 protein activity are biologically relevant because formation of DNA adducts, tumor growth and drug resistance could be altered by differences in enzymatic activity.
This study reports findings in constructs that completely mimic NAT1 mRNA by including the 5'-UTR transcribed by the major promoter (NATb) and 3'-UTRs and ORF of the referent, NAT1*4, and of the most common allele associated with reduced acetylation, NAT1*14B. (Hoffmann et al., 1997) . Although strict federal regulations have banned industrial uses of ABP (IARC, 1987) , ABP can still be found as a contaminant in color additives, paints, food colors, leather, textile dyes, diesel-exhaust particles, cooking oil fumes and commercial hair dyes (Nauwelaers et al., 2011) .
Methods

Experiments in Yeast
In situ N-Acetylation Following Recombinant Expression of Human NAT1 in Yeast.
The ORFs of NAT1*14B and NAT1*4 were recombinantly expressed in the pESP-3 yeast (Schizosaccaromyces pombe) expression system (Stratagene, La Jolla, CA). They were cultured in YES media (Teknova, Hollister, CA, 0.5% yeast extract, 3.0% glucose, 0.0225% adenine, 0.0225% histidine, 0.0225% leucine, 0.0225% uracil, and 0.0225% lysine). To ensure the amount of cells expressing NAT1*4 and NAT1*14B was the same, cell cultures were both grown to an optical density (OD) of 0.40. Cell numbers were calculated based on OD, using the conversion of 1.0 OD (600 nm) corresponds to 2 x 10 7 cells (Stratagene). Aliquots (10 mL) from both the NAT1*4 and NAT1*14B expressing cultures were each treated with ABP to make total volume concentrations of 10, 50 and 100 µM ABP. Samples (100 µl) were collected following 30 minute incubation with ABP. N-acetyl-ABP was separated and quantified by high performance liquid chromatography (HPLC) as described previously .
Experiments in CHO Cells
Polyadenylation Site Removal. The bovine growth hormone polyadenylation site from the pcDNA5/FRT (Invitrogen, Carlsbad, CA) vector was removed to allow the endogenous NAT1 polyadenylation sites to be active. This was accomplished by digestion of pcDNA5/FRT at 37⁰C with restriction endonucleases, ApaI and SphI (New England Biolabs, Ipswich, MA), followed by overhang digestion with T4 DNA polymerase (New England Biolabs) and ligation with T4 Ligase (New England Biolabs).
Preparation of NATb/NAT1*4 Construct. NATb/NAT1*4 construct was created utilizing gene splicing via overlap extension (Horton et al., 1989) Preparation of NATb/NAT1*14B. To construct the NATb/NAT1*14B pcDNA5/FRT plasmid, the NATb/NAT1*4 pcDNA5/FRT and a previously constucted NAT1*14B allelic construct expressed in a yeast vector, pESP-3 (Stratagene, La Jolla, CA) (Fretland et al., 2001), were both incubated at 37⁰C with restriction enzymes, SbfI and AflII (New England Biolabs).
Following restriction digestion, the NATb/NAT1*4 pcDNA5/FRT and the 476 bp segment of NAT1*14B (including G560A) were gel purified and ligated utilizing T4 ligase (New England Biolabs). All constructs were sequenced to ensure integrity of allelic segments and junction sites. These constructs that contain NATb 5'-UTR, coding region of NAT1*4 or NAT1*14B, and μ g/mL aprotinin and 2 mM pepstatin A). The resuspended cell pellet was subjected to 3 rounds of freezing at -80⁰C and thawing at 37⁰C and then centrifuged at 15,000xg for 10 min. In vitro assays using PABA or ABP were conducted and acetylated products were separated utilizing HPLC as previously described . Preliminary studies optimized reactions with respect to linearity of time and protein concentration. PABA and ABP kinetic constants were determined at a fixed concentration of 100 µM acetyl coenzyme A (AcCoA). PABA kinetic constants were determined using varying PABA concentrations between 11.7 -3000 µM. ABP kinetic constants were determined using varying ABP concentrations between 11.7 -3000 µM.
Reactions containing substrate, AcCoA and enzyme were incubated at 37˚C for 10 min.
Reactions were terminated by the addition of 1/10 volume of 1M acetic acid and centrifuged at 15,000Xg for 10 min. Measurements were adjusted according to baseline measurements using lysates of the UV5/CYP1A1 cell line and normalized by the amount of total protein. Protein concentrations were measured using the method of Bradford (Bio-Rad, Hercules, CA). v max , k m , and k cat were determined by fitting substrate concentration and velocity data to the hyperbolic Michaelis-Menten model. All calculations were determined using GraphPad Prism Software version 4 (Graphpad Software, La Jolla, California).
Determination of in situ (Whole-Cell Assay) Kinetic Parameters of NAT1 4 and NAT1 14B. In situ kinetic parameters were determined with a whole cell assay using media spiked with varying concentrations of PABA or ABP. PABA kinetic constants were determined using varying PABA concentrations between 2.25 -300 µM. ABP kinetic constants were determined using varying ABP concentrations between 0.19 and 25 µM. The cells were incubated at 37⁰C and media was collected after 1 h (PABA) or 22 min (ABP), 1/10 volume of 1M acetic acid was added, and the mixture was centrifuged at 13,000Xg for 10 min. Values were normalized to the amount of cells present at time of media removal. Following media removal, cells were washed with 1XPBS, trypsanized, and diluted in counting buffer (aqueous 1% sodium chloride). The number of cells was determined using a Z series Coulter Counter (Beckman Coulter, Indianopolis, IN). The supernatant was injected into the reverse phase HPLC column and N-acetyl-PABA and N-acetyl-ABP were separated and quantitated as described above. v max and k m were determined as described above.
Determination of in vitro Kinetic Parameters of O-acetylation for NAT1 4 and NAT1
14B. Cells and lysates were collected and prepared as described above. N-hydroxy-4-aminobiphenyl (N-OH-ABP) O-acetyltransferase assays were conducted and product was separated from substrate using HPLC as previously described . Assays containing 50 µg total protein, N-OH-ABP, AcCoA, and 1 mg/mL deoxyguanosine (dG) were incubated at 37⁰C for 10 min. N-OH-ABP kinetic constants were determined at a fixed concentration of 100 µM AcCoA and N-OH-ABP concentrations between 0.78 and 200 µM.
Reactions were stopped with the addition of 100 µL of water saturated ethyl acetate and centrifuged at 13,000xg for 10 min. The organic phase was removed, evaporated to dryness, redissolved in 100 µL of 10% ACN and injected onto the HPLC. v max , k m , and k cat were determined as described above. to NAT1 from sample lysate were assumed to be the same. Densitometric analysis was performed using Quantity One Software (Bio-Rad).
DNA Isolation and dG-C8-ABP Quantitation. Cells were prepared as described above. DNA was isolated and dG-C8-ABP adducts were quantitated as previously described (Millner et al., 2011) . Measurement of Cytotoxicity. Assays for cell cytoxicity were carried out as described (Millner et al., 2011) . Stably transfected cells expressing NAT1*4 and NAT1*14B were grown in HAT medium (30 mM hypoxanthine, 0.1 mM aminopterin, and 30 mM thymidine) for 12 doublings. Cells (1x10 6 ) were plated, allowed to grow for 24 h and were then treated with 1.56, 3.13, 6.25 or 12.5 µM ABP (Sigma) or vehicle alone (0.5% DMSO) in media. After 48 h, cells were plated to determine survival following exposure to ABP. To determine cloning efficiency following each dose of ABP, 100 cells were plated in triplicate in 6 well-plates and allowed to grow for 7 days in non-selective media. Colonies were counted and expressed as percent of vehicle control.
This article has not been copyedited and formatted. The final version may differ from this version. The kinetic parameters, apparent k m and k cat also were determined in vitro (per mg NAT1 protein in solution biochemistry) for the referent, NAT1 4 and the variant, NAT1 14B ( Table 2 ).
The apparent k cat of NAT1 14B was lower for PABA (p<0.0001) but higher for N-OH-ABP (p<0.0001) when compared to NAT1 4. There was no significant difference in apparent k cat for ABP between NAT1 14B and NAT1 4 (p>0.05). The apparent k cat /k m of NAT1 14B was lower for PABA (p<0.0001) but higher for ABP (p<0.05) and N-OH-ABP (p<0.0001) when compared to NAT1 4.
Apparent k m and v max for PABA and ABP also were determined in situ (per million cells in a whole cell based assay) for the referent, NAT1 4, and the variant, NAT1 14B (Table 3) substrates including PABA, p-aminosalisylic acid, and various arylamine carcinogens (Fretland et al., 2001; Fretland et al., 2002; Hughes et al., 1998; Zhu and Hein, 2008) . Recombinant NAT1 14B expression in yeast demonstrated lower N-and O-acetylation, NAT1-specific protein levels and increased NAT1 proteasomal degradation (Butcher et al., 2004; Fretland et al., 2001; Fretland et al., 2002) . Similarly, NAT1 14B expressed in COS-1 cells also resulted in less NAT1
N-and O-acetylation, lower NAT1 protein level, and lower PABA v max, but higher PABA k m when compared to the referent, NAT1 4 (Zhu and Hein, 2008) . Our kinetic constant determinations performed in CHO cells confirmed that NAT1 14B results in a lower apparent v max (both in vitro and in situ) for PABA when compared to the referent, NAT1 4. We also confirmed the higher PABA apparent k m in NAT1 14B determined in vitro when compared to NAT1 4. In addition to PABA acetylation, we also report on N-and O-acetylation of ABP and N-OH-ABP. ABP is a human urinary bladder carcinogen found as a contaminant in cigarette smoke, food dyes, paints, textile dyes, engine exhaust, and commercial hair dyes (Nauwelaers, et al., 2011) The arylamine substrate k m of NAT1 is dependent on the AcCoA concentration because acetylation proceeds via a 'ping-pong bi-bi' reaction (Weber and Hein, 1985) . AcCoA concentrations have been measured in vivo in the low micromolar range (Reeves et al., 1988) .
The lowest concentration of AcCoA (100 µM) was used that allowed repeatable and accurate measurements of acetylated product. In order to better mimic NAT1 catalyzed acetylation in vivo, kinetic constants were determined in situ (when possible) allowing the concentration of 1 8 (Fretland et al., 2002) . This result was surprising as previous studies reported NAT1 14B activity and protein expression to be lower than NAT1 4. To further explore the NAT1 14B acetylation status, studies were conducted in stably transfected CHO cells.
When comparing apparent v max (in vitro), the NAT1 14B apparent v max was lower than the NAT1 4 for all substrates studied. The apparent v max describes the maximum enzyme velocity extrapolated to maximum substrate concentrations. The lower apparent v max for PABA, ABP, and N-OH-ABP indicate that at high substrate concentrations, NAT1 14B has a decreased ability to metabolize the substrate when compared to NAT1 4. The apparent v max /k m , or intrinsic clearance, describes an enzyme's ability to metabolize a substrate at substrate concentrations well below the k m and has also been shown to correlate well to human liver clearance (Chen et al., 2011; Northrop, 1999) . caused by a reduction in protein expression. Butcher et. al (2004) reported that NAT1 14B and other NAT1 genetic variants associated with reduced enzymatic activity have reduced ability to be acetylated which resulted in an unstable NAT1 protein. Therefore, NAT1 14B was reported to be less stable and have increased proteasomal degradation compared to NAT1 4 (Butcher et al., 2004) . Our study confirmed that NAT1 14B resulted in reduction of NAT1 protein.
Because determination of kinetic parameters is dependent upon AcCoA concentration, acetylation was measured in situ to allow the concentration of AcCoA to be provided by the cell. Northrop, 1999) . Since low substrate concentrations are relevant in vivo, the higher NAT1 14B apparent v max /k m suggests that differences between NAT1 14B and NAT1 4 catalyzed ABP acetylation should be observed in vivo. Therefore, risk for individuals possessing NAT1*14B is dependent on exposure type and can also be altered depending on exposure level.
NAT1 homology modeling predicted that the R187Q could affect NAT1 active site acetylation and enzymatic activity (Walraven et al., 2008) . Because changes in binding of AcCoA and substrate specificity are likely altered due to the R187Q, it is not surprising that differences in intrinsic clearance between NAT1 14B and NAT1 4 were observed. We confirmed that R187Q modifies substrate affinity, albeit in opposite directions depending on substrate.
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